Howard Sofen

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Diamant Thaçi, Eric L. Simpson, Lisa A. Beck et al. · The Lancet · 2015 · 566 citations

Life Sciences, Dermatology, Immunology +11

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf et al. · Cancer Cell · 2015 · 389 citations · Full text

Medicine, Genetics, Molecular Genetics +15

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Eric L. Simpson, Carsten Flohr, Lawrence F. Eichenfield et al. · Journal of the American Academy of Dermatology · 2018 · 329 citations · Full text

Medicine, Dermatology, Immunology +17